Knowledge Hub

Best-practice articles for Regulatory Affairs, BE, and development teams working with comparator product and FDA-designated Reference Listed Drug (RLD) sourcing.

Practical guidance for regulated development workflows

Explore short, regulator-aware briefings on terminology precision, study planning clarity, and sourcing fundamentals for ANDA and bioequivalence programs.

What Is a Reference Listed Drug (RLD) and Why It Matters in Generic Development

18 Mar 2026

A structured explainer on how the FDA-designated RLD anchors pharmaceutical equivalence, comparator selection, and documentation consistency across development and submission stages.

Read full article
RLD ANDA Bioequivalence

Comparator Drug vs Reference Listed Drug: Key Differences Explained

7 Apr 2026

Clarifies where comparator and RLD terms overlap, where they differ, and why terminology precision helps avoid regulatory ambiguity in multi-market development programs.

Read full article
Comparator Product Regulatory Strategy Traceability

Need comparator or RLD sourcing support for your next program?

Share your target submission market, required timeline, and storage condition needs for an availability response aligned with regulated development use.

Request a Quote

How it works

  1. Step 1 Share molecule, target submission market, and timeline
  2. Step 2 We confirm RLD alignment, batch availability, and expiry window
  3. Step 3 Receive quotation with sourcing origin and documentation scope
  4. Step 4 Approve procurement and shipping conditions
  5. Step 5 Receive product with shipment records and traceability documentation

Read our full process